| Patient | Harriet Tubman |
|---|---|
| Date of birth | 1951-03-01 |
| Identifiers | MRN HR-NI005-SYN; SSN (made up) 000-05-3961 |
| Document date | 2026-11-01 |
| Author | Carmen Ruiz-Delgado, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for lifelong headaches and sudden sleep spells. Concerns: Falls asleep without warning several times a day, which worries her family; Headaches most days have gotten worse over the past year despite daily ibuprofen; Wants to know whether the spells are seizures and does not want medicine that makes her duller. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ibuprofen 200 mg oral tablet, two tablets by mouth most days (self-directed, over the counter) | Two tablets by mouth most days | Oral route | 2025-09-01 to 2026-04-06 | stopped | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a week | Two tablets by mouth as needed, at most 2 days a week | Oral route | 2026-04-06 | active | S |
| Candesartan 8 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-20 to 2026-05-18 | completed | S |
| Candesartan 16 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-18 | active | S |
| Modafinil 100 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-05-18 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Routine EEG: normal background with intermittent left frontal slowing; no epileptiform discharges | 2026-04-20 to 2026-04-20 | completed | S |
| MRI of the brain: old depressed left frontal skull defect with small underlying encephalomalacia; normal hippocampi; no tumor or other lesion | 2026-04-20 to 2026-04-20 | completed | S |
| Ambulatory EEG with video, 72 hours: four typical spells captured, each at sleep onset with no ictal pattern | 2026-05-04 to 2026-05-07 | completed | S |
| Overnight polysomnography: apnea-hypopnea index 4 per hour; no periodic limb movements; REM sleep within 15 minutes of sleep onset | 2026-05-11 to 2026-05-11 | completed | S |
| Multiple sleep latency test: mean sleep latency 4.5 minutes with two sleep-onset REM periods in five naps | 2026-05-12 to 2026-05-12 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-13 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-04-06 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2023-02-06 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 2021-08-16 | Tdap vaccine | completed | S |
| 2026-10-13 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-13 | RSV vaccine, adjuvanted, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| Mid-1830s, at about age 13 | Head injury in her early teens from an iron weight thrown by an overseer; nearly killed, with little or no medical care | D (CLM-0003) |
| From the mid-1830s onward | Headaches and sudden spells of sleep with vivid dreams and visions since the injury, continuing into old age | D (CLM-0004) |
| Retrospective proposal | Temporal lobe epilepsy proposed retrospectively as the cause of the spells; not established | R (CLM-0005) |
| Retrospective proposal, 2023 | Post-traumatic narcolepsy proposed retrospectively in 2023 as an alternative explanation; not established | R (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Falls asleep without warning several times a day, which worries her family | active | S |
| Headaches most days have gotten worse over the past year despite daily ibuprofen | active | S |
| Wants to know whether the spells are seizures and does not want medicine that makes her duller | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-13; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-10-13; Creatinine [Mass/volume] in Serum or Plasma 0.9 on 2026-10-13; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 67 on 2026-10-13; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-10-13; Hemoglobin [Mass/volume] in Blood 12.6 on 2026-04-06; Ferritin [Mass/volume] in Serum or Plasma 88 on 2026-04-06; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-04-06; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 410 on 2026-04-06; PROMIS sleep related impairment - version 1.0 Tscore 55 on 2026-08-17; On how many days in the last 3 months did you have a headache, if headache lasted more than 1 day, count each day [PhenX] 21 on 2026-08-17; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-08-17; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 2 on 2026-04-06; PC-PTSD-5 score [PC-PTSD-5] 2 on 2026-04-06; Total score [MoCA] 26 on 2026-04-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-13; Total score [Mini-Cog] 5 on 2026-10-13; Total score [AUDIT-C] 0 on 2026-10-13 [S]
Strengths and supports: Supports: extended family, her church, and a wide circle of friends [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent sudden sleep episodes since an adolescent traumatic brain injury; narcolepsy without cataplexy due to a medical condition, provisional; historical cause retrospectively disputed | active | provisional | G47.429 | S — Synthetic diagnosis from the modern sleep testing; it echoes, but does not confirm, the R proposal of post-traumatic narcolepsy. |
| Chronic post-traumatic headache since an adolescent head injury | active | confirmed | G44.329 | S — Synthetic modern coding of the documented lifelong headaches. |
| Medication-overuse headache from near-daily ibuprofen, resolved after withdrawal | resolved | confirmed | G44.40 | S — Synthetic finding; resolved by the three-month review. |
| Sequelae of a traumatic brain injury in adolescence, a skull fracture by historical account | active | confirmed | S06.9XAS | S — Synthetic modern coding of the documented injury; the MRI findings in the episode are synthetic. |
| Acute viral gastroenteritis with mild dehydration and a prerenal creatinine rise while taking candesartan, resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-06 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-06 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-06 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 72 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-06 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-06 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-04-06 | Ferritin [Mass/volume] in Serum or Plasma | 88 | ng/mL | 30-400 ng/mL | Normal | S |
| 2026-04-06 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-04-06 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 410 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-04-06 | PROMIS sleep related impairment - version 1.0 Tscore | 68 | {score} | S | ||
| 2026-04-06 | On how many days in the last 3 months did you have a headache, if headache lasted more than 1 day, count each day [PhenX] | 54 | {days} | S | ||
| 2026-04-06 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-04-06 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 2 | {score} | S | ||
| 2026-04-06 | PC-PTSD-5 score [PC-PTSD-5] | 2 | {score} | S | ||
| 2026-04-06 | Total score [MoCA] | 26 | {score} | S | ||
| 2026-05-18 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-18 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-18 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-18 | PROMIS sleep related impairment - version 1.0 Tscore | 67 | {score} | S | ||
| 2026-08-17 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-17 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.88 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-08-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 68 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-17 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-17 | PROMIS sleep related impairment - version 1.0 Tscore | 55 | {score} | S | ||
| 2026-08-17 | On how many days in the last 3 months did you have a headache, if headache lasted more than 1 day, count each day [PhenX] | 21 | {days} | S | ||
| 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.21 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 47 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-13 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-13 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-13 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-13 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-06 | Body height | 152 | cm | S |
| 2026-04-06 | Body weight | 52 | kg | S |
| 2026-04-06 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-04-06 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-04-06 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-04-06 | Heart rate | 72 | /min | S |
| 2026-04-06 | Respiratory rate | 14 | /min | S |
| 2026-04-06 | Body temperature | 36.6 | Cel | S |
| 2026-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-20 | Body height | 152 | cm | S |
| 2026-04-20 | Body weight | 52 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 140 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 70 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-18 | Body height | 152 | cm | S |
| 2026-05-18 | Body weight | 51.5 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 72 | /min | S |
| 2026-05-18 | Respiratory rate | 14 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-17 | Body height | 152 | cm | S |
| 2026-08-17 | Body weight | 51.5 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 76 | /min | S |
| 2026-08-17 | Respiratory rate | 14 | /min | S |
| 2026-08-17 | Body temperature | 36.6 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-28 | Body height | 152 | cm | S |
| 2026-09-28 | Body weight | 50.7 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 90 | /min | S |
| 2026-09-28 | Respiratory rate | 16 | /min | S |
| 2026-09-28 | Body temperature | 37.4 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-13 | Body height | 152 | cm | S |
| 2026-10-13 | Body weight | 51.2 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 74 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-04-06 | Primary care visit for lifelong headaches and sudden sleep spells | finished | S |
| 2026-04-20 | Neurology consultation with EEG and brain MRI | finished | S |
| 2026-05-18 | Review of ambulatory EEG and sleep studies; four-week headache check | finished | S |
| 2026-08-17 | Three-month sleepiness and headache review | finished | S |
| 2026-09-28 | Same-day sick visit for vomiting and diarrhea | finished | S |
| 2026-10-13 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Neurology referral for lifelong spells after a head injury, to decide whether they are seizures or sleep attacks | completed | GL-AAN-SEIZURE-2015 | S |
| Obtain a routine EEG and brain MRI, then capture typical spells on ambulatory EEG with video; start antiseizure medicine only if the spells prove epileptic | completed | GL-AAN-SEIZURE-2015 | S |
| Overnight polysomnography followed by a multiple sleep latency test to evaluate excessive daytime sleepiness | completed | GL-AASM-HYPERSOMNOLENCE-2021 | S |
| Start modafinil 100 mg each morning with two scheduled 15-minute naps a day; check blood pressure and heart rate at follow-up | completed | GL-AASM-HYPERSOMNOLENCE-2021 | S |
| Stop daily ibuprofen, limit acute treatment to 2 days a week, and keep a headache diary | completed | GL-ICHD3-2018, GL-AHS-2021 | S |
| Start non-sedating headache prevention with candesartan, titrated after a potassium and creatinine check | completed | GL-AHS-2021 | S |
| Screen mood, anxiety, trauma symptoms, and cognition at baseline with a trauma-informed approach, and repeat the PHQ-9 at follow-up | completed | GL-AAN-SEIZURE-2015, GL-AASM-HYPERSOMNOLENCE-2021 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Stop daily over-the-counter analgesics and limit acute headache medicine to no more than 2 days a week | 2026-05-18 | completed | No ibuprofen since the first visit; acetaminophen about once a week | S |
| Cut headache days by at least half by the three-month review | 2026-08-17 | completed | Headache days fell from 54 to 21 in three months | S |
| Reduce daytime sleep attacks and lower the PROMIS sleep-related impairment T-score below 60 | 2026-08-17 | completed | T-score fell from 68 to 55; one or two planned naps a day and rare unplanned episodes | S |
| Establish whether the spells are epileptic before considering antiseizure medicine | 2026-05-18 | completed | Typical spells captured on ambulatory EEG were sleep onset; no antiseizure medicine needed | S |